SORT1 and ovarian carcinoma: However, currently, SORT1-targeting agents have recently entered a clinical trial phase regarding thyroid, breast, and ovarian cancer patient populations, where the effects of this adjuvant therapy have been shown to enhance the effect of existing chemotherapy, permitting the targeted entry of a peptide conjugated to docetaxel (TH1902) [156,157,158,159].